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Abstract
Background: Given the size of the HIV epidemic in South Africa and other developing countries,
scaling up antiretroviral treatment (ART) represents one of the key public health challenges of the
next decade. Appropriate priority setting and budgeting can be assisted by economic data on the
costs and cost-effectiveness of ART. The objectives of this research were therefore to estimate
HIV healthcare utilisation, the unit costs of HIV services and the cost per life year (LY) and quality
adjusted life year (QALY) gained of HIV treatment interventions from a provider's perspective.
Methods: Data on service utilisation, outcomes and costs were collected in the Western Cape
Province of South Africa. Utilisation of a full range of HIV healthcare services was estimated from
1,729 patients in the Khayelitsha cohort (1,146 No-ART patient-years, 2,229 ART patient-years)
using a before and after study design. Full economic costs of HIV-related services were calculated
and were complemented by appropriate secondary data. ART effects (deaths, therapy
discontinuation and switching to second-line) were from the same 1,729 patients followed for a
maximum of 4 years on ART. No-ART outcomes were estimated from a local natural history
cohort. Health-related quality of life was assessed on a sub-sample of 95 patients. Markov modelling
was used to calculate lifetime costs, LYs and QALYs and uncertainty was assessed through
probabilistic sensitivity analysis on all utilisation and outcome variables. An alternative scenario was
constructed to enhance generalizability.
Results: Discounted lifetime costs for No-ART and ART were US$2,743 and US$9,435 over 2 and
8 QALYs respectively. The incremental cost-effectiveness ratio through the use of ART versus No-
ART was US$1,102 (95% CI 1,043-1,210) per QALY and US$984 (95% CI 913-1,078) per life year
gained. In an alternative scenario where adjustments were made across cost, outcome and
utilisation parameters, costs and outcomes were lower, but the ICER was similar.
Conclusion: Decisions to scale-up ART across sub-Saharan Africa have been made in the absence
of incremental lifetime cost and cost-effectiveness data which seriously limits attempts to secure
funds at the global level for HIV treatment or to set priorities at the country level. This article
presents baseline cost-effectiveness data from one of the longest running public healthcare
antiretroviral treatment programmes in Africa that could assist in enhancing efficient resource
allocation and equitable access to HIV treatment.
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Background
Antiretroviral treatment has been shown to be effective in
reducing morbidity and mortality in patients infected
with HIV in developing countries [1]. However, in sub-
Saharan Africa where 25.8 million are HIV-infected [2]
only 17% of those in need of ART were using treatment by
the end of 2005 [3]. Although progress has been made in
extending coverage, the United Nations General Assembly
target of universal access to antiretroviral treatment (ART)
by 2010 for all in need [4] presents a formidable chal-
lenge.
Given the scale of treatment envisaged, the paucity of data
estimating the lifetime costs and efficiency of HIV treat-
ment is a serious hindrance to effective planning. In the
absence of data, most global estimates of resource needs
have been based on normative modelling exercises and in
publishing these estimates, authors have urgently recom-
mended primary research into the costs and cost-effective-
ness of ART to address these gaps [5,6].
The objectives of this research were to estimate the utilisa-
tion and costs of HIV-related healthcare, to estimate life-
time costs, life years and quality adjusted life years
(QALYs) and to assess cost-effectiveness from the pro-
vider's perspective by comparing treatment and prophy-
laxis of opportunistic and HIV-related illnesses without
antiretrovirals (hereafter "No-ART") to costs and effects
when ARVs are used ("ART") based on primary unit cost,
utilisation, health-related quality of life (HRQoL) and
outcome data from a cohort accessing care in a resource
poor setting in South Africa.
Methods
Study design
This study undertakes a cost-effectiveness analysis from a
provider's perspective. The utilisation of a full range of
HIV-related services was calculated using a before and
after study design. Full economic costs were calculated
using the ingredients and step-down methods. Markov
modelling – an approach to extrapolating data [7] – was
used to calculate lifetime costs, LYs, QALYs and incremen-
tal cost-effectiveness ratios (ICERs). Costs and effects are
presented for zero and 3 percent annual discount rates.
Multi-way and probabilistic sensitivity analyses were used
to assess uncertainty.
Study population and description of interventions
Patients included in this study live in Khayelitsha, a town-
ship on the outskirts of Cape Town characterised by a high
proportion of informal housing and lack of access to basic
services. The level of unemployment in the area is esti-
mated to be 46% [8]. In April 2000, three HIV clinics were
opened within existing public sector clinics to provide
treatment and prophylaxis of HIV-related and opportun-
istic infections and events, counselling and support
groups for HIV-positive people. Prophylactic medication
included trimethoprim-sulphamethoxazole and flucona-
zole for eligible patients. Acute infections were managed
at the clinics but severely ill patients were referred to sec-
ondary and tertiary hospitals. Patients suspected of having
tuberculosis (TB) were referred to TB facilities.
In May 2001, the service was extended to include ART for
patients with CD4 counts less than 200 cells/μl at any
WHO stage or with WHO stage IV and any CD4 level. This
was the first public sector programme offering ART in
South Africa and experience from this initiative has
informed the development of local ART guidelines. ART
patients continued to receive treatment and prophylaxis
for acute infections and appropriate referrals once initi-
ated on ART.
Healthcare utilisation
Healthcare utilisation, including HIV clinic visits, TB treat-
ment and inpatient care, was established using a before
and after study design. This means that ART patients were
used as their own control – the pre-ART period was used
to calculate No-ART utilisation while the post-baseline
period informed ART estimates. While a clinical trial com-
paring No-ART to ART would be the gold standard for
measuring utilisation, obvious ethical limitations imply
that the before and after study design is one of the only
possible choices in this context. The delay between the
start of the project in 2000 and the introduction of ART in
2001, as well as the limited number of patients on ART in
the early years of the project ensure that utilisation prior
to initiation of ART is reflective of general HIV care in the
absence of ART.
HIV clinic utilisation and associated 95% confidence
intervals was calculated from 1,729 patients with 1,146
No-ART patient years and 2,229 ART patient years of fol-
low-up over a median No-ART and ART follow-up of 0.63
years (IQR 0.33–1.32, max 4.35) and 1.03 years (IQR
0.68 – 1.70, max 4.08) respectively. Data on the use of
inpatient and tuberculosis care required extensive valida-
tion. This validation was undertaken on a sub-sample of
670 patients, with 501 No-ART patient-years and 693 ART
patient-years. One would anticipate that patients who
died would receive the highest concentration of inpatient
care around this time. However, with a before and after
study design, by definition there are no deaths in the No-
ART group who are in reality a pre-ART group. We have
accounted for this by calculating a separate "cost of dying"
from a sample of 83 patients who had been using services
in the HIV clinics but had died before being able to start
ART. These patients were followed up at hospitals to
establish their utilisation of inpatient care in the 6-month
period preceding death. The same procedure was followedCost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
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for the 81 patients on ART who died of HIV-related causes.
This approach ensures that inpatient utilisation at the
time of death is not underestimated.
Unit costs of clinic visits, inpatient care and tuberculosis 
treatment
Costing has been undertaken from a provider's perspec-
tive. This means that all direct health care costs and costs
of non-governmental organisations have been included,
but that direct non health care costs (such as patient travel
and time costs) have been excluded [9]. Unit costs of
health services are defined as the full economic cost per
ART or No-ART visit, per inpatient day at tertiary and sec-
ondary/district facilities and per tuberculosis case treated.
Costing of HIV clinic services was undertaken separately
for ART and No-ART visits. Costing of TB treatment was
undertaken at the Nyanga clinic, and was supplemented
with secondary data [10]. Nyanga clinic was chosen
because 67% of TB patients have an HIV-positive diagno-
sis which is the highest in the area. Khayelitsha patients
are referred to Tygerberg Academic Hospital, Groote Sch-
uur Hospital (tertiary) and to GF Jooste Hospital (second-
ary/district) for inpatient care. Costing of HIV inpatient
care was undertaken at Tygerberg and secondary data
informed costs for Groote Schuur and GF Jooste [11-13].
Each unit cost has been categorised into patient-specific,
clinical staff (medical officers and nurses), overhead and
capital components. Patient-specific costs include medi-
cines (curative and prophylactic excluding ARVs which
have been calculated separately), laboratory investiga-
tions (excluding ART safety and monitoring laboratory
tests which have also been calculated separately), imaging
and procedures. Mean patient-specific unit costs were cal-
culated by multiplying physical units of resources con-
sumed with their market values (assumed to be equivalent
to opportunity costs). The following market values have
been used:
￿ Medicine costs from provincial government tender
prices
￿ Laboratory test costs from National Health Laboratory
Services (NHLS). The NHLS is the provider of laboratory
services to the public health system.
￿ Imaging and procedure costs from the Uniform Patient
Fee Schedule [14] which details the fees to be charged to
private patients in public sector hospitals – private fee
scales are based on costs.
Prescriptions for curative and prophylactic medicines and
multivitamins were extracted from the records of 60
patients who had been on ART for at least one year. This
amounted to a medicine costing sample of 757 visits for
No-ART patients and 1,532 visits for ART patients. Tuber-
culosis patient-specific resource use (medicines, X-rays
and diagnostic tests) was based on South African national
TB treatment protocols [15]. Additional patient-specific
resources that were prescribed to TB patients (acute non-
TB medicines) and clinical staff costs for TB initiation and
monitoring visits were derived from HIV-positive TB
patients. At the tertiary hospital, HIV-related patient-spe-
cific resource use was collected by medical officers and
entered onto specifically designed data collection tools.
Sixty-one patients with 243 inpatient days were included
in the analysis. At the secondary/district hospital, patient-
specific cost data were derived from a secondary source
[11].
We define overhead costs to include recurrent costs that
are not directly related to patient numbers including util-
ities (water, electricity) and non-clinical staff (administra-
tive, cleaning and security personnel). Under the
assumption that all patients utilise a similar amount of
overheads during each visit or inpatient day, overhead
costs have been calculated by establishing overhead
expenditure from routine facility accounting data and
dividing this by total patient visits and/or inpatient days.
All data were measured over an annual period to mini-
mise biases that might result from seasonal variations in
expenditure, visits or inpatient days. For hospitals,
expenditure was first allocated between inpatient and out-
patient departments using the patient-day equivalent
method [16] which amounts to assuming that an inpa-
tient day requires just under four-times more overhead
resources than an outpatient department or emergency
visit. This ratio is based on primary data collection in
Western Cape hospitals.
Clinical staff – including medical officers and nurses – are
likely to be a key constraint in attaining universal access to
HIV-related care [17]. At clinics, clinical staff requirements
were estimated by timing 54 ART visits, 94 No-ART visits,
and 25 treatment initiation/monitoring visits for HIV-
positive patients at the TB clinic. This estimate of the time
per clinical consultation was multiplied against the aver-
age clinical staff cost per minute (adjusted for annual
working days and patient contact hours) to calculate a
clinical staff cost per visit. At the inpatient level, it was
more difficult to calculate an HIV-specific clinical staff
cost owing to restrictions on researcher access to hospital
wards. At the secondary hospital, we established the
number of full time equivalent doctors and nurses in each
relevant ward and their average cost of employment. The
resultant cost was split equally between inpatients in these
wards. At the tertiary hospital, we established the annual
expenditure on medical officers and allocated this to inpa-
tient days using the patient-day equivalent method.Cost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
Page 4 of 14
(page number not for citation purposes)
Capital costs relate to the costs of medical equipment, fur-
niture and buildings. Following costing literature [18],
these were calculated by establishing the replacement
value of each item, estimating the working life and annu-
atizing using an 8% real interest rate (the return on South
African long-term government bonds). The resultant
annual cost was allocated to inpatient days and clinic vis-
its using the same method as for overheads.
Costs were expressed in 2003 prices and converted to US$
using an average 2003 exchange rate (US$1 = 7.56 Rands)
[19]. Any inflation adjustments used the consumer price
index excluding mortgage bonds [20].
The costs of ARVs and monitoring and safety laboratory 
investigations
The regimen of choice for patients starting ART in Khay-
elitsha has changed over time. Whereas previously all
patients started on a nucleoside reverse transcriptase
inhibitor (NRTI) backbone of zidovudine and lamivu-
dine, this has been replaced by stavudine and lamivudine
in line with national ART guidelines [21], and so the
nationally recommended NRTI backbone was costed. As
the national guidelines allow for flexibility in the choice
of non-nucleoside reverse transcriptase inhibitors
(NNRTIs -nevirapine or efavirenz) to accompany the
NRTI backbone, primary data were used to determine the
relative use of NNRTIs. The second-line regimen consists
of zidovudine, didanosine and lopinavir/ritonavir. Labo-
ratory investigation requirements have been based on
national guidelines [21].
Public sector ARV costs (including delivery costs to the
provincial depots) were sourced from the South African
national ARV tender [22]. It is expected that this current
tender will be extended until end of February 2008 after
which time a new tender will be introduced which might
alter current prices depending on the outcomes of negoti-
ations between the government and pharmaceutical com-
panies (Liezl Channing, Pharmacist – HIV/AIDS/STI/TB
Programmes – Western Cape Provincial Government, per-
sonal communication). Laboratory investigation costs
have been sourced from the National Health Laboratory
Services.
Study models
Lifetime results are an important consideration in plan-
ning the resource needs for scaling-up ART – if life-expect-
ancy is underestimated, this will underestimate the
numbers of patients remaining in care which will ulti-
mately lead to severely constrained budgets. Lifetime costs
and outcomes have been calculated with the aid of
Markov modelling. Markov models consist of mutually
exclusive and collectively exhaustive health (Markov)
states with transition probabilities describing all possible
or relevant movements between these states. Transitions
occur after discrete time periods, known as Markov cycles.
Markov states are defined such that "patients" in the state
have a similar risk of events of importance to the disease
in question (e.g. death) and similar costs of healthcare.
When the model is constructed, healthcare costs and
health outcomes are attached to each Markov state. For
example, if one is modelling QALYs using a three-month
Markov cycle, 0.25 (representing three months in a year)
would be multiplied by the appropriate HRQoL value and
attached to each state (with the exception of "dead"). Sim-
ilarly, the cost of being in each Markov state is computed
for the length of the Markov cycle and is attached to the
state. When the model is run over a large number of
cycles, lifetime costs and outcomes are calculated [7,23].
For the ART model, separate Markov states have been
specified for CD4 50–199 cells/μl, and CD4 < 50 cells/μl
because these categories have been shown to be associated
with different mortality rates in large cohort analyses
[24,25]. States have also been stratified according to the
amount of time a patient has been on ART. This stratifica-
tion was required because mortality is concentrated dur-
ing the first six months on ART and decreases dramatically
thereafter [1]. Similarly, the costs of healthcare were
found to be higher closer to the time of ART-initiation
because patients had higher rates of HIV clinic visits, inpa-
tient care and TB treatment.
To adequately capture the trend in costs and outcomes
related to duration on ART, the CD4-based Markov states
were sub-divided into temporary states, known as tunnel
states. During the first 6 month period, tunnel states were
created both for each Markov cycle (i.e. 3-month period)
and for each CD4 category. After 6 months on ART, differ-
ences related to baseline CD4 levels were less significant,
and the CD4 states were merged. However, differences in
mortality rates and costs were still significantly related to
duration on ART, necessitating the ongoing use of tunnel
states for duration periods of between 6 and 48 months
on treatment. Separate states for the second-line regimen
were also created to capture differences in ARV regimen
costs.
The No-ART model was stratified into CD4-based Markov
states of CD4 50–199 cells/μl and CD4 < 50 cells/μl, with
death as the absorbing state.
The proportion of patients entering the models with CD4
50–199 cells/μl versus CD4 < 50 cells/μl has been based
on the baseline CD4 counts of ART patients in the HIV
clinics. Models have been developed in TreeAge Pro® 2005
and are depicted in figure 1.Cost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
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Markov models for No-ART and ART Figure 1
Markov models for No-ART and ART. All: All patients. FL: First-line ART regimen; SL: Second-line ART regimen; 0–3; 3–
6; 6–12; 12–24; 24–36; 36–48; and >48 refer to months since the initiation of ART
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Transition probabilities
Transition probabilities in a Markov model are required
to specify all relevant movements between Markov states
– as depicted by the arrows in figure 1. In the ART model,
transition probabilities together with 95% confidence
intervals were estimated from Kaplan Meier product limit
estimates of survival for 1,729 patients accessing ART in
the first 48 months of the Khayelitsha programme. A
probability of dying was calculated directly from primary
data in months 0–3, 3–6, 6–12, 12–24, 24–36 and 36–48.
This allowed an accurate specification of the decline in
mortality over four years on ART. Patients who were lost
to follow-up were treated statistically as deaths. This over-
estimate of mortality might be more reflective of routine
care settings where adherence to treatment might be lower
and loss to follow-up might be higher. Probabilities of
switching to the second-line regimen were calculated from
primary data separately for months 6–12, 12–24, 24–36
and 36–48. No patients switched to second-line between
months 0 and 6.
Given that the majority of patients still remain in care at
48 months on ART, the long-term effectiveness of ART,
rates of failure of first-line regimens and costs and out-
comes after treatment failure will be unknown for the
foreseeable future. We have extrapolated death transition
probabilities by calculating the average probability of
dying between baseline and 48 months. This probability
has been applied uniformly to all periods on treatment
thereafter. This approach could underestimate life-expect-
ancy which we consider pragmatic given the many uncer-
tainties. Similarly, the second-line transition probabilities
were extrapolated by calculating an average probability
between baseline and 48 months.
Transition probabilities for the No-ART model were
derived from the Cape Town AIDS Cohort, a local natural
history cohort of 981 ART-naïve patients who presented at
an HIV clinic established at the New Somerset secondary
hospital in Cape Town between 1992 and 2000 [26,27].
These secondary data sources provide Kaplan Meier sur-
vival estimates for patients with CD4 < 200 cells/μl and
CD4 < 50 cells/μl, but not for patients with CD4 50–199
cells/μl. However, data indicates that a CD4 < 50 cells/μl
is associated with a hazard ratio for death of 2.28 (p =
0.021) [28]. We used this hazard ratio to estimate the
probability of dying with CD4 50–199 cells/μl as equal to
the probability of dying with CD4 < 200 cells/μl divided
by the hazard ratio. The probability of switching between
CD4 50–199 cells/μl and CD4 < 50 cells/μl was estimated
to ensure that overall survival was in line with survival
with CD4 < 200 cells/μl.
The final death transition probabilities required in each
intervention are the probabilities of dying from non-HIV
related causes. These were calculated from South African
life tables [29] according to the age, gender and socio-eco-
nomic status of patients included in this analysis.
Health-related quality of life
This analysis has expressed outcomes as both LYs and
QALYs. QALYs are calculated by weighting life-expectancy
by a factor relating to the health-related quality of that life
(HRQoL) in relation to a number of aspects of health such
as functional, physical and emotional status. The overall
rationale for using QALYs is that HIV-positive people on
ART have been shown to fare more favourably in relation
to quality of life as well as life expectancy than those who
are not receiving ART (see [30,31]). HRQoL has been
measured in a related study [32] using a widely validated
instrument called the EQ-5D on a sub-sample of ART
patients in the same cohort at baseline 3, 6 and 12 months
(n = 95, 97, 98 and 83 respectively). HRQoL data were
converted to utilities using health state values derived
from a United Kingdom general population survey using
the time trade-off method [33].
Assessing uncertainty
This analysis is subject to uncertainty relating to the data
requirements of the study, generalizability of results,
extrapolation of data and choice of analytic methods.
Uncertainty relating to data requirements has been
assessed using probabilistic sensitivity analysis (PSA).
This technique propagates parameter and underlying
modelling uncertainty through the model by means of
first and second-order Monte Carlo simulation. First-
order simulations capture the different paths taken by
"patients" in the model in order to capture variability
associated with the structure of the model. Second-order
Monte Carlo simulation captures parameter uncertainty –
distributions are specified on all transition probabilities
and utilisation variables and a different value from each
distribution is chosen during each simulation. When a
number of simulations are run, overall parameter uncer-
tainty is captured as confidence intervals around lifetime
costs, outcomes and ICERs [34,35]. Simulations have
been run using 1,000 distribution values, and each distri-
bution value has been subjected to 10,000 first-order sim-
ulations. Distributions for transition probabilities and
utilisation rates were specified as triangular distributions
spanning the 95% confidence interval for each estimate,
with the mode equal to the estimate in each instance.
Uncertainty relating to generalizability of results is con-
cerned with the extent to which the results of this study
can be applicable to other settings. Generalizability has
been assessed by comparing ART outcomes to other pub-
lished low income cohorts [1,36] and No-ART outcomes
to a review of natural history data [37]. Inpatient and visit
utilisation has been compared to a published South Afri-Cost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
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can cost-effectiveness analysis [38] and to national guide-
lines for follow-up of patients on ART [21]. Unit costs
have been compared to other South African studies
[10,13,39]. Where disagreement between this study and
published data has been found, adjustments have been
made through the construction of an alternative scenario.
While no extrapolation is required to estimate outcomes
for No-ART patients, uncertainty relating to extrapolation
is an important problem in the evaluation of ART. This
form of uncertainty has been assessed by comparing ART
outcomes from this study to other published studies.
The final source of uncertainty relates to analytic meth-
ods. These include methods for valuing and measuring
HRQoL and methods for discounting costs and outcomes.
This study has considered uncertainty relating to HRQoL
measurement and valuation by estimating outcomes as
LYs and QALYs and by presenting results discounted at
zero and 3 percent annual rates.
Results
Healthcare utilisation, unit costs and costs in Markov 
states
During the follow-up period, No-ART patients had 12,508
visits to the HIV clinics, 1,342 inpatient days and 159
treated episodes of tuberculosis. ART patients had 39,450
HIV clinic visits, 840 days in hospital and 86 TB episodes.
Patients who died spent between 3 and 6 days in hospital
in the six-months leading up to death.
This data (including 95% confidence intervals) is
expressed per patient-quarter in each Markov state in table
1. In the ART intervention, health service utilisation was
highest for patients with CD4 < 50 cells/μl during the ini-
tial stages on treatment, with 10.5 clinic visits including
pre-ART work-up, 1.1 days in hospital and 0.08 tubercu-
losis cases in the first 3 months. Patients commencing
ART with CD4 50–199 cells/μl had 9.7 clinic visits, 0.6
days in hospital and 0.06 cases of tuberculosis. All health-
care utilisation dropped significantly as duration on ART
increased with only 2.6 clinic visits, 0.1 inpatient days and
0.02 tuberculosis cases per patient-quarter in the third
year. Sixty-one percent of patients received a first-line reg-
imen of stavudine, lamivudine and efavirenz and the
remainder received stavudine, lamivudine and nevirap-
ine. All patients received zidovudine, didanosine and
lopinavir/ritonavir in the second-line regimen.
No-ART patients with CD4 < 50 cells/μl had 3.4 clinic vis-
its, 0.7 inpatient days, and 0.1 tuberculosis cases per
patient-quarter. Patients with CD4 50–199 cells/μl used
less health care. All patients spent between 4 and 6 days in
hospital prior to death.
Full economic unit costs for HIV clinic visits, inpatient
care and TB treatment are presented in table 2. The cost
per HIV clinic visit was US$19 for patients on ART and
US$20 for those not on ART. The average cost per inpa-
tient day was US$267 at the tertiary hospital and US$119
at the district/secondary hospital. Seventy-one percent of
referrals were to the latter, leading to an average weighted
cost of US$162 per inpatient day. The cost per tuberculo-
sis case treated was US$622. The proportion of each unit
cost relating to doctors and nurses ranged between 4% for
TB treatment and 34% for ART clinic visits. The annual
cost of the efavirenz containing first-line regimen was
US$438 per annum whereas the nevirapine containing
regimen cost US$162 per annum. Second-line was more
than double the cost of first-line, at US$952 per annum.
Laboratory investigations including monitoring (CD4
and viral load) and safety tests (ALT, full blood counts,
fasting cholesterol and triglyceride and fasting glucose as
required for each ARV) cost around US$25 per patient-
quarter (see table 1).
The cost per patient-quarter in each Markov state has been
calculated by multiplying healthcare utilisation against
unit costs (table 1). ART costs were highest for patients
with CD4 < 50 cells/μl during the first three months on
treatment, at US$548 excluding costs for patients who
died. Costs remained steady at just over US$170 per quar-
ter from 12 months onwards while patients remained on
first-line, but increased to over US$340 per quarter when
second-line treatment was initiated. No-ART costs in the
CD4 < 50 cells/μl category were US$239 per patient-quar-
ter excluding patients who died. A mean cost of over
US$1000 was incurred at hospitals for No-ART patients
during the period preceding death.
Effectiveness
Table 3 provides an overview of transition probabilities.
Sixty-three percent of patients initiated ART with CD4 50–
199 cells/μl and the remainder with CD4 counts < 50
cells/μl. Similar results have been found in other develop-
ing country cohorts [1]. No patients were changed to sec-
ond-line during the first 6 months, but by 48 months,
16% of those surviving had switched. Deaths were con-
centrated in the first year. At six months on ART, 83.9% of
the 643 patients initiating with a CD4 count < 50 cells/μl
were alive in comparison with 93.9% of those initiating
with CD4 50–199 cells/μl. The product limit estimate of
survival was 86.9%, 83.4% and 76.2% at 12, 24 and 48
months respectively. Fifty percent of No-ART patients
with CD4< 200 cells/μl were alive at 24 months. HRQoL
values increased from 0.7 at baseline to 0.85 by 12
months on ART as shown in table 4.C
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Table 1: Quarterly healthcare utilisation and total costs in each health state including antiretrovirals and associated laboratory investigations (US$)
Health state Clinic visits Inpatient days Tuberculosis treatment ARV Cost
(95% CI)
Safety and 
monitoring 
laboratory costs
Cost per Markov state 
(95%CI)
Additional cost for dying patients
Mean visits
(95%CI)
Cost
(95%CI)
Mean IP days
(95%CI)
Cost
(95%CI)
Mean cases
(95%CI)
Cost
(95%CI)
Mean IP days
(95%CI)
Cost
(95%CI)
ART CD4 < 50 cells/μl 
months 0–3
10.5
(10.2–10.7)
199
(194–204)
1.09
(0.96–1.25)
177
(155–201)
0.08
(0.05–0.12)
48
(30–76)
72.7
(70.2–75.1)
52 548
(502–609)
4.0
(1.7–6.2)
704
(306–1102)
ART CD4 < 50 cells/μl 
months 3–6
3.7
(3.5–3.8)
70
(67–73)
0.77
(0.66–0.90)
125
(107–146)
0.04
(0.02–0.08)
25
(13–49)
72.7
(70.2–75.1)
0 293
(257–343)
4.0
(1.7–6.2)
704
(306–1102)
ART CD4 50–199 cells/
μl months 0–3
9.7
(9.5–9.9)
184
(181–188)
0.6
(0.52–0.7)
98
(84–114)
0.06
(0.04–0.1)
38
(24–60)
72.7
(70.2–75.1)
52 444
(410–488)
4.0
(1.7–6.2)
704
(306–1102)
ART CD4 50–199 cells/
μl months 3–6
3.5
(3.3–3.6)
66
(64–68)
0.12
(0.09–0.17)
20
(14–27)
0.02
(0.01–0.04)
11
(4–26)
72.7
(70.2–75.1)
0 169
(152–196)
4.0
(1.7–6.2)
704
(306–1102)
First-line ART months 
6–12
3.6
(3.5–3.7)
69
(67–70)
0.21
(0.18–0.24)
33
(29–39)
0.02
(0.01–0.03)
13
(8–21)
72.7
(70.2–75.1)
24 212
(198–229)
4.0
(1.7–6.2)
704
(306–1102)
Second-line ART 
months 6–12
3.6
(3.5–3.7)
69
(67–70)
0.21
(0.18–0.24)
33
(29–39)
0.02
(0.01–0.03)
13
(8–21)
238 28 381
(370–397)
4.0
(1.7–6.2)
704
(306–1102)
First-line ART months 
12–24
2.7
(2.65–2.8)
52
(50–53)
0.1
(0.08–0.13)
17
(14–20)
0.02
(0.01–0.03)
12
(8–20)
72.7
(70.2–75.1)
24 178
(167–193)
4.0
(1.7–6.2)
704
(306–1102)
Second-line ART 
months 12–24
2.7
(2.65–2.8)
52
(50–53)
0.1
(0.08–0.13)
17
(14–20)
0.02
(0.01–0.03)
12
(8–20)
238 28 347
(338–360)
4.0
(1.7–6.2)
704
(306–1102)
First-line ART months 
24–36
2.6
(2.5–2.7)
49
(47–51)
0.1
(0.08–0.13)
17
(14–20)
0.02
(0.01–0.03)
12
(8–20)
72.7
(70.2–75.1)
24 175
(164–191)
4.0
(1.7–6.2)
704
(306–1102)
Second-line ART 
months 24–36
2.6
(2.5–2.7)
49
(47–51)
0.1
(0.08–0.13)
17
(14–20)
0.02
(0.01–0.03)
12
(8–20)
238 28 344
(335–358)
4.0
(1.7–6.2)
704
(306–1102)
First-line ART beyond 
36 months
2.8
(2.6–3.0)
52
(49–56)
0.1
(0.08–0.13)
17
(14–20)
0.02
(0.01–0.03)
12
(8–20)
72.7
(70.2–75.1)
24 179
(165–196)
4.0
(1.7–6.2)
704
(306–1102)
Second-line ART 
beyond 36 months
2.8
(2.6–3.0)
52
(49–56)
0.1
(0.08–0.13)
17
(14–20)
0.02
(0.01–0.03)
12
(8–20)
238 28 348
(337–363)
4.0
(1.7–6.2)
704
(306–1102)
No-ART CD4 < 50 
cells/μl
3.4
(3.2–3.5)
66
(63–68)
0.7
(0.64–0.75)
113
(104–122)
0.1
(0.07–0.13)
60
(46–79)
N/A N/A 239
(213–269)
5.7
(3.5–8.0)
1023
(626–1422)
No-ART CD4 50–199 
cells/μl
2.6
(2.5–2.6)
51
(49–52)
0.3
(0.28–0.32)
49
(45–52)
0.07
(0.06–0.09)
45
(37–55)
N/A N/A 145
(132–159)
5.7
(3.5–8.0)
1023
(626–1422)
IP: Inpatient daysCost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
Page 9 of 14
(page number not for citation purposes)
Table 3: Transition probabilities (per three-month period) and data sources
Input parameters Data sources Transition probability (range)
CD4 category at baseline for ART and No-ART
CD4 < 50 cells/ml 0.372 (0.349–0.395)
CD4 50–199 cells/ml 0.628 (0.605–0.651)
Probabilities of transitioning between alive Markov states
First-line regimen to second-line regimen
0–6 months N/A – no patients switched
6–12 months 0.48% switched by 12 months 0.002 (0.001–0.006)
12–24 months 4.66% switched by 24 months 0.011 (0.007–0.015)
24–36 months 11.73% switched by 36 months 0.019 (0.014–0.026)
36–48 months 15.9% switched by 48 months 0.012 (0.005–0.024)
>48 months Average over 0–48 months 0.011 (0.007–0.017)
No-ART, CD4 50–199 cells/ml to CD4 < 50 cells/ml
all quarters Calculated to ensure 50% surviving at 24 
months
0.040 (0.026–0.043)
Probabilities of transitioning to dead Markov states
ART CD4 < 50 cells/ml
0–3 months 86.9% surviving at 3 months 0.131 (0.107–0.159)
3–6 months 83.9% surviving at 6 months 0.034 (0.031–0.038)
ART CD4 50–199 cells/ml
0–3 months 95.9% surviving at 3 months 0.041 (0.030–0.054)
3–6 months 93.9% suriviving at 6 months 0.021 (0.019–0.024)
All patients on ART, irrespective of regimen
6–12 months 86.9% suriviving at 12 months 0.018 (0.017–0.020)
12–24 months 83.4% suriviving at 24 months 0.010 (0.008–0.012)
24–36 months 79.5% surviving at 36 months 0.012 (0.009–0.016)
36–48 months 76.2% suriviving at 48 months 0.010 (0.005–0.017)
>48 months Average over 0–48 months 0.017 (0.013–0.021)
No ART CD4 count < 50 cells/ml
all quarters 20% surviving at 24 months1 0.182 (0.147–0.227)
No ART CD4 50–199 cells/ml
all quarters 50% surviving at 24 months with CD4 < 200 
cells/ml2 divided by hazard ratio3
0.039 (0.034–0.043)
1 No-ART survival with CD4 < 50 cells/μl from Post, Wood et al [52]
2 No-ART survival with CD4 < 200 cells/μl from Badri, Bekker et al [27]
3 Hazard ratio for death in CD4 < 50 versus 50–199 cells/μl from Coetzee, Hildebrand et al [26]
Table 2: Unit costs of clinic visits, inpatient days and tuberculosis treatment (US$)
Cost categories Clinic visits Inpatient care TB treatment
ART No-ART Tertiary Secondary
Patient-specific 1.65 5.57 28.97 27.66 100.80
Clinical staff 6.64 6.12 35.93 17.86 31.07
Overheads 9.41 5.80 125.46 54.05 488.10
Capital 1.63 1.44 102.91 31.44 1.57
Unit cost 19.33 18.92 293.27 131.02 621.54Cost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
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Lifetime costs, outcomes, cost-effectiveness and 
probabilistic sensitivity analysis
Table 5 shows lifetime costs, outcomes and cost-effective-
ness results. Undiscounted life years were 2.9 and 12.9
while discounted QALYs (3 percent annual rate) were 1.9
and 8.0 for No-ART and ART respectively. Discounted per-
patient lifetime costs were US$2,743 for No-ART versus
US$9,435 for ART. The discounted ICER on ART was
US$1,102 per QALY gained. The ICER was lower per LY
gained, and slightly higher when costs and effects were
discounted at a zero rate. Sensitivity around the dis-
counted incremental cost per QALY gained is summarized
in a cost-effectiveness acceptability curve in Figure 2. This
curve shows the proportion of ICERs derived through
probabilistic sensitivity analysis that are lower than alter-
native levels of willingness to pay per QALY gained. While
no simulations produced ICERs below US$1,000, all sim-
ulations indicate that ART would be cost-effective at a
willingness to pay of US$1,300 per QALY gained.
The results of probabilistic sensitivity analysis are pre-
sented as confidence intervals around these results (see
table 5). These indicate that there are distinct increases in
lifetime costs and outcomes from implementing ART as
opposed to No-ART.
Results from multi-way sensitivity analysis
We compared our results to those of similar studies to
identify which values to adjust in the sensitivity analysis.
Given the many uncertainties surrounding the extrapola-
tion of outcomes on ART, a review of studies using
Markov modelling was specifically undertaken. In these
studies, undiscounted outcomes on ART ranged between
5.8 [40] and 18.8 LYs [38] while the majority of studies
calculated outcomes between 14 and 15 LYs [41-43]. In
those studies that only presented outcomes that were dis-
counted (all at 3% per annum) the lowest estimate of LYs
was 5.3 [44] but most studies reported outcomes of 10–11
years [45,46]. ART outcomes in this study are therefore
comparable with those reported in other modelling stud-
ies.
In terms of survival on ART, our primary data indicated
86.9%, 83.4% and 76.2% surviving at 12, 24 and 48
months and extrapolated results indicated 71% surviving
at 60 months. These outcomes are slightly worse than
results from a 7-year Senegalese cohort study [36] which
indicated 88.3%, 82.6% and 75.4% at 12, 24 and 60
months respectively, but given the higher baseline CD4
counts of the Senegalese patients, results are comparable.
HRQoL values were also highly comparable to estimates
from another Cape Town cohort where HRQoL was meas-
ured with the SF36 instrument and valued using a United
Kingdom-based standard gamble algorithm (see [38]).
Unit costs were also similar to other local studies
[10,13,39].
Although our results are in line with the literature, most
studies in the literature themselves are derived from non-
routine settings. We have therefore constructed an alterna-
tive scenario to give insights into potential costs and out-
comes in routine settings and other developing countries.
A meta-analysis of developing country ART cohorts indi-
cated that our survival rates at 12 months may be higher
than in other settings. In Khayelitsha, 13% of the cohort
had died by 12 months but no patients were lost to fol-
Table 5: Lifetime costs (US$), effectiveness and ICERs of ART compared to No-ART
Treatment 
option
Lifetime costs (95%CI) Outcomes ICER†
Life Years (95%CI) QALYs (95%CI) Life Years (95%CI) QALYs (95%CI)
Undiscounted
No-ART 2,966 (2,611–3,343) 2.9 (2.6–3.3) 2.1 (1.8–2.3)
ART 13,191 (11,167–16,056) 12.9 (11.1–15.2) 10.8 (9.1–12.5) 1,023 (958–1,116) 1,166 (1,092–1,279)
Discounted
No-ART 2,743 (2,414–3,057) 2.7 (2.4–3.0) 1.9 (1.7–2.1)
ART 9,435 (8,414–10,891) 9.5 (8.5–10.7) 8.0 (7.3–8.6) 984 (913–1,078) 1,102 (1,043–1,210)
Lifetime costs and effectiveness are per patient in each group.
† The ICER is calculated as incremental lifetime costs divided by incremental effectiveness.
Table 4: HRQoL values
Health state Value
ART 0–3 months 0.71
ART 3–6 months 0.81
ART 6–12 months 0.82
ART >12 months 0.85
No-ART 0.71
HRQoL measurements from Jelsma et al [32] and values from Dolan 
et al [33].Cost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
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low-up. Across developing country cohorts, 6% had died
by 12 months and 12% had been lost to follow-up giving
a combined 18% dead and lost to follow-up which is 37%
higher than in Khayelitsha [1]. Given that the high patient
retention found in Khayelitsha would not necessarily be
generalizable to other developing countries, we have con-
servatively increased all probabilities of dying by 37% to
estimate a worst-case scenario. Our No-ART outcomes
have been based on 50% survival at 24 months for
patients with CD4 < 200 cells/μl whereas a review of
developing country data reported median survival of 11
months across studies [37]. Death transition probabilities
were adjusted accordingly in the sensitivity analysis.
While inpatient utilisation was similar to published data,
outpatient utilisation was higher [38]. ART visits were
adjusted to be in line with recommendations in national
treatment guidelines (6 during the first three months and
3 per patient-quarter thereafter) [21] and No-ART visits
were decreased to 1.4 per quarter in CD4 50–199 cells/μl
and 1.9 per quarter in CD4 < 50 cells/μl to be in line with
published estimates. Finally, all inpatient care has been
assumed to occur at secondary level hospitals given that
tertiary level facilities are not accessible to the majority of
South Africans.
In this alternative scenario, lifetime costs were reduced by
over US$1000 for No-ART and by nearly US$4000 on
ART. No-ART life expectancy decreased by 0.6 and ART
life-expectancy decreased by 3.2. While lifetime costs and
outcomes were reduced, the overall impact on ICERs was
small (see table 6).
Discussion
This study is one of the first to estimate the cost-effective-
ness of comprehensive HIV care including ART based on
primary  cost, utilisation and HRQoL data from a large
cohort in a developing country setting. This study has
introduced a number of enhancements to standard
Markov modelling approaches that have been used in
developed country ART cost-effectiveness analyses. These
include the creation of tunnel states to capture the rapidly
diminishing utilisation and mortality through the first
years on ART, and the provision of Markov states that
reflect the strict two ARV-regimen approach to care con-
tained in the WHO and South African national ART guide-
lines. The modelling has also introduced the concept of
capturing the important cost-driver of inpatient care
through  transition costs, which are incurred as patients
transition from a Markov state to death. Probabilistic sen-
Cost-effectiveness acceptability curve Figure 2
Cost-effectiveness acceptability curve.
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sitivity analysis has captured data uncertainty with 95%
confidence intervals around lifetime costs, outcomes and
ICERs.
Our findings that formed inputs to the Markov model,
such as unit costs and HRQoL estimates, were comparable
to other studies. Where variations between our findings
and those of other studies were identified, these variables
were adjusted in the sensitivity analysis. One variable that
differed in our findings compared to other studies is
patient utilisation rates. Although utilisation of clinic vis-
its in this study may appear high compared to other data,
it is worth reflecting on the model of care, where clinical
visits were to a combined doctor-nurse team, and patients
were triaged as to whether or not it was necessary for them
to see a doctor at each visit. This differs from settings
where visits are counted only as those in which a doctor is
consulted.
While the public health setting, clinical eligibility criteria
and clinical protocols used in Khayelitsha make results
from this analysis highly relevant to other South African
public care settings, it is possible that Khayelitsha patients
had better access to HIV clinic services and other special
treatment that enhanced patient retention. The multi-way
sensitivity analysis, used to construct a scenario with
much more conservative outcomes and lower utilisation,
reveals that the main findings on the ICER are robust
when these assumptions are simultaneously varied.
In a setting where access to ART is optimal, the before-
and-after study design could result in a selection bias
whereby patients with advanced disease who have not yet
accessed ART do not adequately represent patients who
never access ART. The delay between the launch of the
service and the availability of ART together with the huge
unmet demand for ART in this study ensured however
that the pre-ART period was representative of patients
who did not access ART at all. The exception is costs asso-
ciated with death due to the survivor bias inherent in the
design, which were explicitly addressed by the inclusion
of transition costs associated with death
This study has some limitations that can be addressed in
future research. Guidelines recommend that costing be
undertaken from a societal perspective in order to include
direct non-healthcare costs such as transport and time
costs incurred by patients travelling and receiving treat-
ment in a primary health care facility or in hospital [9].
Data from two local studies [39,47] indicate that patients
incurred US$0.40 in direct travel expenses and US$0.85 in
travelling time costs per visit. Across a patient's lifetime,
the net present value of these costs would be US$38 and
US$141 for No-ART and ART respectively. Thus while
public sector HIV clinic services and tuberculosis treat-
ment are free at the point of use in South Africa, patient
costs might still pose barriers that could limit universal
access to care and could have negative implication for
patient retention and adherence. Government policy [48]
has indicated a willingness to provide patient transport or
to subsidize patient costs in certain circumstances but this
policy has yet to be implemented. We therefore recom-
mend that additional research be undertaken into the full
range of non-healthcare costs imposed on patients in
order to inform policy development in this area.
The further interpretation of cost-effectiveness results in
terms of allocative efficiency requires caution. Generally,
this would require an assessment of whether QALYs
gained on ART were a good buy given the level of the
ICER, either by reference to government policy on the
maximum willingness to pay for a QALY or by comparing
to other published cost per QALY analyses. In South
Africa, lack of government policy precludes the first
option and paucity of local cost per QALY studies pre-
cludes the second. However, the Commission on Macr-
oeconomics and Health [49] has recommended that an
ICER below per capita gross domestic product (GDP)
could be considered to be very cost-effective. South
Africa's GDP of US$ 3,089 [50] puts ART well below this
Table 6: Lifetime costs (US$), effectiveness and ICERs in alternative scenario
Treatment option Lifetime costs Outcomes ICER
Life Years QALYs Life Years QALYs
Undiscounted
Generalized No-ART 1,813 2.3 1.6
Generalized ART 9,474 9.7 8.1 1,035 1,184
Discounted
Generalized No-ART 1,706 2.1 1.5
Generalized ART 7,215 7.6 6.3 1,016 1,148Cost Effectiveness and Resource Allocation 2006, 4:20 http://www.resource-allocation.com/content/4/1/20
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threshold with the implication that ART is allocatively
efficient. In addition, if ARV price reductions are achieved
in future government ARV tenders, the cost-effectiveness
of ART will be further enhanced.
We would argue however that equity is as important as
efficiency when allocating resources to HIV treatment.
Over six million South Africans are HIV-positive and will
be in need of treatment within the next 10 years with the
implication that an equity goal of universal access for all
in need by 2010 is a formidable challenge. We therefore
recommend additional research into the cost-effectiveness
of less resource intensive ART options such as nurse driven
as opposed to doctor driven treatment, possibly limiting
access to first-line [51] and/or limiting or simplifying
expensive laboratory testing. While these options might
be less effective, in instances where there are financial con-
straints to universal access to ART, social values should
determine whether we as Africans think it is fairer to offer
comprehensive treatment to fewer patients or universal
access to a more limited package of benefits. The very
question of financial constraints becomes a political and
societal value question in the context of the extent of mor-
bidity and mortality being faced in Southern Africa as a
consequence of HIV.
Conclusion
Universal ARV provision has major resource implications
for developing countries, particularly in Africa. To date,
decisions on ARV programs have been made in a context
of extremely limited economic primary-data evidence.
This paper provides detailed results (from analysis of pri-
mary data) on utilisation of healthcare on and off ART,
full economic costs of HIV-related services, primary out-
comes on ART over 48 months and extrapolated lifetime
costs, LYs and QALYs, which could contribute to evi-
dence-informed decision-making. While the ICER for ART
compared to No-ART in this research provides strong sup-
port for the South African government's universal ARV
treatment policy, in the context of our level of economic
development, aspects of the treatment guidelines (e.g. less
resource intensive models of care and regimens) should
be further explored if ART is to be equitably scaled-up and
universal access achieved.
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